皮克诺格诺®可以缓解糖尿病患者的慢性静脉功能不全 (CVI):补充剂注册研究
Gianni Belcaro1,2, Maria R Cesarone3,4, Claudia Scipione3,4
1Irvine3 and Nicolaides Labs, Circulation Sciences, Pescara, Italy - cardiovascularresearchint@gmail.com.
Minerva surgery
|September 11, 2024
概括
在糖尿病患者中,Pycnogenol®显著改善了慢性静脉功能不全 (CVI) 和微循环. 这种天然补充剂提供了一种安全有效的压缩替代方案,用于管理CVI症状.
科学领域:
- 血管医学 血管医学
- 糖尿病学 糖尿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性静脉功能衰竭 (CVI) 和糖尿病微血管病变在糖尿病患者中很常见.
- 糖尿病患者CVI的有效管理策略对于预防并发症至关重要.
- Pycnogenol®是一种具有潜在治疗益处的天然补充剂.
研究的目的:
- 评估Pycnogenol®在治疗CVI和糖尿病微血管病的疗效.
- 评估CVI的糖尿病患者的微循环参数.
- 为了比较Pycnogenol®与标准管理和弹性压缩.
主要方法:
- 一项非干预性注册研究,比较Pycnogenol® (150 mg/天) 加标准管理 (SM) 与弹性压缩加SM 8周.
- 包括58名患有CVI的糖尿病患者,其中28名在Pycnogenol®组和30名在对照组.
- 测量包括微循环参数 (皮肤休息流量,脚胀,PO2,PCO2) 和临床分数 (CSS,VCSS,VDS).
主要成果:
- 与弹性压缩相比,Pycnogenol®显著改善了微循环输液 (P<0.05).
- 通过CSS,VCSS和VDS评估的临床症状在使用Pycnogenol®时显著减少.
- 没有观察到任何副作用,但Pycnogenol®的服药性和耐受性很高.
结论:
- 在患有CVI的糖尿病患者中,Pycnogenol®显示出显著的临床和微循环疗效.
- 它作为CVI的宝贵补充治疗,可能预防.
- 该研究强调了Pycnogenol®在治疗这种普遍疾病中的作用.
相关概念视频
01:27Parentral Nutrition: Centeral and Peripheral Parental Nutrition
108
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
108
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160